View Older Stories View More Recent Stories

Oct 29, 2020 10:00AM Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress
Oct 29, 2020 07:00AM Concert Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020
Oct 22, 2020 07:14AM Concert Pharma (CNCE) Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology
Oct 22, 2020 07:00AM Concert Pharmaceuticals Announces Publication on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology
Oct 13, 2020 07:00AM Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress
Sep 29, 2020 07:00AM Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophrenia
Sep 8, 2020 07:00AM Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 18, 2020 06:00AM Concert Pharmaceuticals to Present at The JMP Securities CNS Forum
Aug 6, 2020 07:00AM Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update
Jul 30, 2020 07:00AM Concert Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 6, 2020
Jun 12, 2020 04:03PM Concert Pharma (CNCE) Announces Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata
Jun 12, 2020 04:01PM Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata
May 26, 2020 07:00AM Concert Pharmaceuticals to Webcast Fireside Chat at Jefferies Virtual Global Healthcare Conference
May 12, 2020 07:00AM Concert Pharmaceuticals to Webcast Presentation at UBS Virtual Healthcare Conference
Apr 30, 2020 07:00AM Concert Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Update on Clinical Programs
Apr 23, 2020 07:00AM Concert Pharmaceuticals to Report First Quarter 2020 Financial Results on April 30, 2020
Apr 1, 2020 07:01AM Concert Pharma (CNCE) Reports Plans for CTP-543 Phase 3 Trials in Alopecia Areata
Apr 1, 2020 07:00AM Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata
Feb 27, 2020 07:00AM Concert Pharmaceuticals Reports 2019 Financial Results and Provides Update on Clinical Programs
Feb 24, 2020 07:00AM Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at the 2020 American Academy of Dermatology Annual Meeting
Feb 20, 2020 07:00AM Concert Pharmaceuticals to Report Full Year 2019 Results on February 27, 2020
Jan 27, 2020 04:04PM Concert Pharma (CNCE) Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543
Jan 27, 2020 04:01PM Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543
Jan 22, 2020 08:40AM Concert Pharma (CNCE) Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata
Jan 22, 2020 08:40AM Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata
Dec 19, 2019 04:05PM Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata
Dec 2, 2019 07:02AM Concert Pharma (CNCE) Commences CTP-692 Phase 2 Trial in Schizophrenia
Dec 2, 2019 07:00AM Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia
Nov 12, 2019 07:00AM Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 7, 2019 07:00AM Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update
Nov 6, 2019 07:00AM Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia
Oct 31, 2019 07:00AM Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019
Oct 14, 2019 06:19AM Concert Pharma (CNCE) Highlights Positive Phase 2 Data in Alopecia Areata
Oct 12, 2019 03:15AM Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress
Oct 2, 2019 07:00AM Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference
Sep 23, 2019 07:00AM Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer
Sep 17, 2019 07:04AM Concert Pharma (CNCE) Reports Complete Enrollment in 2nd Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing
Sep 17, 2019 07:00AM Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata
Sep 12, 2019 07:01AM Concert Pharma (CNCE) Reports CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation
Sep 12, 2019 07:00AM Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress
Sep 3, 2019 07:01AM Concert Pharma (CNCE) Announces Positive CTP-543 Results from Phase 2 Alopecia Areata Trial
Sep 3, 2019 07:00AM Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial
Aug 29, 2019 07:00AM Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 1, 2019 07:00AM Concert Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update
Jul 25, 2019 07:00AM Concert Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 1, 2019
Jun 12, 2019 07:03AM Concert Pharma (CNCE) Announces Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers
Jun 12, 2019 07:00AM Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers
Jun 5, 2019 07:00AM Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
May 16, 2019 07:00AM Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
May 14, 2019 07:00AM Concert Pharmaceuticals to Present at Upcoming Investor Conferences
View More Recent Stories View Older Stories